- Consumer Products
- Latest 5.92
- Currency US$
- Change 0.05
- Percent Change 0.852 %
- Volume 2,054,305
- Fri Mar 14, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
12 months ended Dec 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Feb 24||$-0.43||May 14||$-0.34|
12 months ended Mar 16, 2014.
A look at major corporate events and financial announcements that are coming up.
About the Company
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.